



## Clinical trial results:

**A phase IV, open label, randomized, multicountry study to evaluate immunogenicity and safety of GSK Biologicals' seasonal (2010-2011) influenza vaccine Fluarix<sup>TM</sup> in children previously vaccinated with GSK Biologicals' H1N1 vaccine (Pandemrix<sup>TM</sup>)**

### Summary

EudraCT number	2010-020330-26
Trial protocol	SE NL
Global end of trial date	26 May 2011

### Results information

Result version number	v1
This version publication date	15 April 2016
First version publication date	30 January 2015

### Trial information

#### Trial identification

Sponsor protocol code	114451
-----------------------	--------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01196026
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, 1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000725-PIP01-09
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 September 2011
Is this the analysis of the primary completion data?	Yes
Primary completion date	26 May 2011
Global end of trial reached?	Yes
Global end of trial date	26 May 2011
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate HI immune response against the H1N1 strain 28 days following vaccination with the first dose of trivalent inactivated influenza virus (TIV) vaccine (Fluarix) in subjects previously vaccinated with 2 doses of H1N1 adjuvanted vaccine (Pandemrix).

Protection of trial subjects:

All subjects were supervised for 30 min after vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Only eligible subjects that had no contraindications to any components of the vaccines were vaccinated.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 September 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 80
Country: Number of subjects enrolled	Sweden: 82
Worldwide total number of subjects	162
EEA total number of subjects	162

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	54
Children (2-11 years)	108
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Primed subjects =subjects who had been previously vaccinated with a seasonal influenza vaccine whereas unprimed subjects had not. - children  $\geq 9$  years + primed children  $< 9$  years=1 dose of Fluarix - unprimed children  $< 9$  years=2 doses of Fluarix. To complete the vaccination schedule, a 2nd dose of Havrix vaccine was given outside the study setting

### Pre-assignment

Screening details:

162 subjects were enrolled in the study but only 154 subjects were vaccinated. The remaining 8 subjects gave their consent withdrawal and were not included in the study. Enrollment was stratified according to the age at first Pandemrix vaccination: 6-11 months, 12-35 months, 3-9 years. Also, subjects were grouped from 3-5 and from 6-9 years.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Fluarix 6-11 Months Group

Arm description:

Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.

Arm type	Experimental
Investigational medicinal product name	Havrix™ Junior
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Two intramuscular injections

Investigational medicinal product name	Fluarix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Two intramuscular injections

<b>Arm title</b>	Fluarix 12-35 Months Group
------------------	----------------------------

Arm description:

Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.

Arm type	Experimental
Investigational medicinal product name	Fluarix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details: One or two intramuscular injections.	
Investigational medicinal product name	Havrix™ Junior
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details: Two intramuscular injections.	
<b>Arm title</b>	Fluarix 3-9 Years Group
Arm description: Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.	
Arm type	Experimental
Investigational medicinal product name	Fluarix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details: One or two intramuscular injections.	
Investigational medicinal product name	Havrix™ Junior
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details: Two intramuscular injections.	
<b>Arm title</b>	Havrix Junior 6-11 Months Group
Arm description: Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.	
Arm type	Active comparator
Investigational medicinal product name	Havrix™ Junior
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details: Two intramuscular injections.	
<b>Arm title</b>	Havrix Junior 12-35 Months Group
Arm description: Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.	
Arm type	Active comparator
Investigational medicinal product name	Havrix™ Junior
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details: Two intramuscular injections.	

<b>Arm title</b>	Havrix Junior 3-9 Years Group
Arm description:	
Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.	
Arm type	Active comparator
Investigational medicinal product name	Havrix™ Junior
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Two intramuscular injections.	

<b>Number of subjects in period 1<sup>[1]</sup></b>	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group
Started	10	44	23
Completed	9	36	23
Not completed	1	8	0
Consent withdrawn by subject	1	4	-
Unspecified	-	1	-
Lost to follow-up	-	3	-

<b>Number of subjects in period 1<sup>[1]</sup></b>	Havrix Junior 6-11 Months Group	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group
Started	10	43	24
Completed	10	42	24
Not completed	0	1	0
Consent withdrawn by subject	-	-	-
Unspecified	-	-	-
Lost to follow-up	-	1	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 8 subjects were enrolled but not vaccinated due to consent withdrawal after randomization.

## Baseline characteristics

### Reporting groups

Reporting group title	Fluarix 6-11 Months Group
Reporting group description: Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.	
Reporting group title	Fluarix 12-35 Months Group
Reporting group description: Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.	
Reporting group title	Fluarix 3-9 Years Group
Reporting group description: Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.	
Reporting group title	Havrix Junior 6-11 Months Group
Reporting group description: Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.	
Reporting group title	Havrix Junior 12-35 Months Group
Reporting group description: Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.	
Reporting group title	Havrix Junior 3-9 Years Group
Reporting group description: Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.	

Reporting group values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group
Number of subjects	10	44	23
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
arithmetic mean	1	2.3	6.4
standard deviation	± 0	± 0.52	± 1.99
Gender categorical Units: Subjects			
Female	5	21	13
Male	5	23	10

Reporting group values	Havrix Junior 6-11 Months Group	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group
Number of subjects	10	43	24
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
arithmetic mean	1	2.4	7.5
standard deviation	± 0	± 0.58	± 1.53
Gender categorical Units: Subjects			
Female	4	16	13
Male	6	27	11

Reporting group values	Total		
Number of subjects	154		
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over	0 0 0 0 0 0 0 0		
Age continuous Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical Units: Subjects			
Female	72		
Male	82		

## End points

### End points reporting groups

Reporting group title	Fluarix 6-11 Months Group
Reporting group description: Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.	
Reporting group title	Fluarix 12-35 Months Group
Reporting group description: Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.	
Reporting group title	Fluarix 3-9 Years Group
Reporting group description: Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.	
Reporting group title	Havrix Junior 6-11 Months Group
Reporting group description: Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.	
Reporting group title	Havrix Junior 12-35 Months Group
Reporting group description: Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.	
Reporting group title	Havrix Junior 3-9 Years Group
Reporting group description: Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.	
Subject analysis set title	Fluarix All Ages Group
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.	
Subject analysis set title	Havrix Junior All Ages Group
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.	

### Primary: Haemagglutination Inhibition (HI) Antibody Titers Against H1N1 in All Subjects Receiving Fluarix Vaccine

End point title	Haemagglutination Inhibition (HI) Antibody Titers Against H1N1 in All Subjects Receiving Fluarix Vaccine <sup>[1]</sup>
End point description: Antibody titers were expressed as Geometric mean titers (GMTs).	
End point type	Primary
End point timeframe: Day 0 and 28	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.	



<b>End point values</b>	Fluarix All Ages Group			
Subject group type	Subject analysis set			
Number of subjects analysed	65			
Units: Titer				
geometric mean (confidence interval 95%)				
Day 0	120.7 (100.8 to 144.4)			
Day 28	1079.3 (915.8 to 1272)			

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of Subjects Seropositive for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine

End point title	Number of Subjects Seropositive for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine <sup>[2]</sup>
End point description:	Seropositivity was defined as antibody titers greater than or equal to 1:10.
End point type	Primary
End point timeframe:	Day 0-28

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

<b>End point values</b>	Fluarix All Ages Group			
Subject group type	Subject analysis set			
Number of subjects analysed	65			
Units: Subjects				
Day 0	65			
Day 28	65			

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of Subjects Seroprotected for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine

End point title	Number of Subjects Seroprotected for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine <sup>[3]</sup>
-----------------	--

End point description:

A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.

End point type	Primary
End point timeframe:	
Day 0-28	
Notes:	
[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.	

<b>End point values</b>	Fluarix All Ages Group			
Subject group type	Subject analysis set			
Number of subjects analysed	65			
Units: Subjects				
Day 0	63			
Day 28	65			

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of Subjects Seroconverted for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine

End point title	Number of Subjects Seroconverted for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine <sup>[4]</sup>
End point description:	
A seroconverted subject was defined as a subject that had either a prevaccination (Day 0) titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer.	
End point type	Primary
End point timeframe:	
Day 28	
Notes:	
[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.	

<b>End point values</b>	Fluarix All Ages Group			
Subject group type	Subject analysis set			
Number of subjects analysed	65			
Units: Subjects				
subjects	55			

### Statistical analyses

No statistical analyses for this end point

### Primary: Mean Geometric Increase (MGI) in HI Antibody Titers Against H1N1 in All

## Subjects Receiving Fluarix Vaccine

End point title	Mean Geometric Increase (MG I) in HI Antibody Titers Against H1N1 in All Subjects Receiving Fluarix Vaccine <sup>[5]</sup>
-----------------	--

End point description:

MG I was defined as the geometric mean of the within-subject ratios of the post-vaccination (Day 28) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer.

End point type	Primary
----------------	---------

End point timeframe:

Day 28

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

<b>End point values</b>	Fluarix All Ages Group			
Subject group type	Subject analysis set			
Number of subjects analysed	65			
Units: Ratio				
geometric mean (confidence interval 95%)				
Ratio	8.9 (7.1 to 11.2)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: HI Antibody Titers Against All Fluarix Vaccine Strains

End point title	HI Antibody Titers Against All Fluarix Vaccine Strains
-----------------	--

End point description:

Antibody titers were expressed as GMTs. Vaccine strains included in the analysis were Flu A/CAL/7/09 H1N1 , FluB/Bri/60/08 Victoria, and Flu A/Vic/210/09 H3N2, further in this summary denoted as H1N1, Victoria and H3N2 strains, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)

<b>End point values</b>	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	35	23	10
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1 Day 0	176.6 (79.3 to 393.4)	124.9 (97.1 to 160.5)	102 (77.2 to 134.9)	171.4 (118.9 to 247.2)
H1N1 Day 28	1810.2 (775.2 to 4226.8)	1345 (1141.9 to 1584.1)	659.7 (524.1 to 830.3)	0 (0 to 0)

Victoria Day 0	16.4 (3.7 to 71.9)	15.1 (10.6 to 21.5)	21.9 (14 to 34.1)	13.6 (7.6 to 24.6)
Victoria Day 28	176.8 (28.1 to 1111.2)	142.2 (93.5 to 216.2)	188.8 (103.7 to 343.8)	0 (0 to 0)
H3N2 Day 0	5 (5 to 5)	21.2 (13.7 to 32.8)	31 (19 to 50.5)	5 (5 to 5)
H3N2 Day 28	88.4 (35.9 to 217.6)	448.3 (265.9 to 755.8)	518.6 (304.1 to 884.3)	0 (0 to 0)

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group	Fluarix All Ages Group	Havrix Junior All Ages Group
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	43	24	65	77
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1 Day 0	186.5 (148.8 to 233.8)	105.3 (75.4 to 147)	120.7 (100.8 to 144.4)	154.4 (129.8 to 183.7)
H1N1 Day 28	0 (0 to 0)	0 (0 to 0)	1079.3 (915.8 to 1272)	0 (0 to 0)
Victoria Day 0	19.1 (14.4 to 25.4)	19.1 (12.3 to 29.6)	17.4 (13.2 to 22.8)	18.3 (14.8 to 22.7)
Victoria Day 28	0 (0 to 0)	0 (0 to 0)	160.9 (115 to 225.2)	0 (0 to 0)
H3N2 Day 0	8.9 (6.4 to 12.4)	26.7 (16.6 to 42.9)	20.8 (15.2 to 28.3)	11.7 (8.9 to 15.2)
H3N2 Day 28	0 (0 to 0)	0 (0 to 0)	396.3 (276.3 to 568.5)	0 (0 to 0)

## Statistical analyses

No statistical analyses for this end point

## Secondary: HI Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine

End point title	HI Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine
-----------------	---

End point description:

Antibody titers were expressed as GMTs. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 0 and Month 6

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	28	22	9
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1 Day 0 (N=6;28;22;9;38;23;56;70)	201.6 (81.1 to 501.1)	126.4 (93.2 to 171.4)	96.9 (73.9 to 126.9)	172.8 (113.9 to 262.1)
H1N1 Month 6 (N=6;28;22;9;38;23;56;70)	1437 (595.7 to 3466.6)	565.5 (458.1 to 698.2)	335.5 (253.1 to 444.7)	93.4 (48.6 to 179.5)
Victoria Day 0 (N=6;28;22;0;0;0;56;0)	17.8 (2.9 to 110)	16.2 (10.6 to 24.6)	21.6 (13.6 to 34.5)	0 (0 to 0)
Victoria Month 6 (N=6;28;22;0;0;0;56;0)	302 (115.6 to 788.8)	148.4 (97.9 to 225.1)	134.5 (82.2 to 220.1)	0 (0 to 0)
H3N2 Day 0 (N=6;28;22;0;0;0;56;0)	5 (5 to 5)	20.3 (12.4 to 33)	29.7 (17.9 to 49.2)	0 (0 to 0)
H3N2 Month 6 (N=6;28;22;0;0;0;56;0)	127 (70.1 to 230)	160 (119.1 to 214.8)	252.7 (186.3 to 342.8)	0 (0 to 0)

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group	Fluarix All Ages Group	Havrix Junior All Ages Group
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	38	23	56	70
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1 Day 0 (N=6;28;22;9;38;23;56;70)	195.6 (155.1 to 246.6)	100.3 (71.8 to 140.1)	119.7 (97.9 to 146.3)	154.6 (128.8 to 185.5)
H1N1 Month 6 (N=6;28;22;9;38;23;56;70)	172 (127.9 to 231.4)	74.3 (55.4 to 99.6)	509 (416.9 to 621.5)	120.7 (97.2 to 149.8)
Victoria Day 0 (N=6;28;22;0;0;0;56;0)	0 (0 to 0)	0 (0 to 0)	18.3 (13.5 to 24.8)	0 (0 to 0)
Victoria Month 6 (N=6;28;22;0;0;0;56;0)	0 (0 to 0)	0 (0 to 0)	154.1 (115.3 to 205.9)	0 (0 to 0)
H3N2 Day 0 (N=6;28;22;0;0;0;56;0)	0 (0 to 0)	0 (0 to 0)	20.3 (14.5 to 28.2)	0 (0 to 0)
H3N2 Month 6 (N=6;28;22;0;0;0;56;0)	0 (0 to 0)	0 (0 to 0)	186.8 (152.9 to 228.2)	0 (0 to 0)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Seropositive for HI Antibodies Against All Fluarix Vaccine Strains

End point title	Number of Subjects Seropositive for HI Antibodies Against All Fluarix Vaccine Strains
-----------------	---

End point description:

Seropositivity was defined as antibody titers greater than or equal to 1:10. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.

End point type	Secondary
End point timeframe:	
Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)	

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	35	23	10
Units: Subjects				
H1N1 Day 0	7	35	23	10
H1N1 Day 28	7	35	23	0
Victoria Day 0	4	25	20	9
Victoria Day 28	7	35	23	0
H3N2 Day 0	0	22	19	0
H3N2 Day 28	7	35	23	0

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group	Fluarix All Ages Group	Havrix Junior All Ages Group
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	43	24	65	77
Units: Subjects				
H1N1 Day 0	43	24	65	77
H1N1 Day 28	0	0	65	0
Victoria Day 0	39	20	49	68
Victoria Day 28	0	0	65	0
H3N2 Day 0	11	19	41	30
H3N2 Day 28	0	0	65	0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Seropositive for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine

End point title	Number of Subjects Seropositive for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine
End point description:	
Seropositivity was defined as antibody titers greater than or equal to 1:10. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.	
End point type	Secondary
End point timeframe:	
Day 0 and Month 6	

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	28	22	9
Units: Subjects				
H1N1 Day 0 (N=6;28;22;9;38;23;56;70)	6	28	22	9
H1N1 Month 6 (N=6;28;22;9;38;23;56;70)	6	28	22	9
Victoria Day 0 (N=6;28;22;0;0;0;56;0)	3	21	19	0
Victoria Month 6 (N=6;28;22;0;0;0;56;0)	6	28	22	0
H3N2 Day 0 (N=6;28;22;0;0;0;56;0)	0	17	18	0
H3N2 Month 6 (N=6;28;22;0;0;0;56;0)	6	28	22	0

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group	Fluarix All Ages Group	Havrix Junior All Ages Group
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	38	23	56	70
Units: Subjects				
H1N1 Day 0 (N=6;28;22;9;38;23;56;70)	38	23	56	70
H1N1 Month 6 (N=6;28;22;9;38;23;56;70)	38	23	56	70
Victoria Day 0 (N=6;28;22;0;0;0;56;0)	0	0	43	0
Victoria Month 6 (N=6;28;22;0;0;0;56;0)	0	0	56	0
H3N2 Day 0 (N=6;28;22;0;0;0;56;0)	0	0	35	0
H3N2 Month 6 (N=6;28;22;0;0;0;56;0)	0	0	56	0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Seroconverted for HI Antibodies Against All Fluarix Vaccine Strains in All Subjects Receiving Fluarix Vaccine

End point title	Number of Subjects Seroconverted for HI Antibodies Against All Fluarix Vaccine Strains in All Subjects Receiving Fluarix Vaccine <sup>[6]</sup>
-----------------	---

End point description:

A seroconverted subject was defined as a subject that had either a pre-vaccination (Day 0) titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 28

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was analysed only for the Fluarix groups i.e. Fluarix 6-11 Months Group, Fluarix 12-35 Months Group, Fluarix 3-9 Years Group and Fluarix All Ages Group.

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Fluarix All Ages Group
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	7	35	23	65
Units: Subjects				
H1N1	5	31	19	55
Victoria	7	30	18	55
H3N2	7	35	22	64

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Seroconverted for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine

End point title	Number of Subjects Seroconverted for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine
-----------------	---

End point description:

A seroconverted subject was defined as a subject that had either a pre-vaccination (Day 0) titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 6

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	28	22	9
Units: Subjects				
H1N1(N=6;28;22;9;38;23;56;70)	5	18	12	0
Victoria (N=6;28;22;0;0;0;56;0)	5	22	15	0
H3N2 (N=6;28;22;0;0;0;56;0)	6	22	18	0

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group	Fluarix All Ages Group	Havrix Junior All Ages Group
------------------	----------------------------------	-------------------------------	------------------------	------------------------------



Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	38	23	56	70
Units: Subjects				
H1N1(N=6;28;22;9;38;23;56;70)	1	0	35	1
Victoria (N=6;28;22;0;0;0;56;0)	0	0	42	0
H3N2 (N=6;28;22;0;0;0;56;0)	0	0	46	0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Seroprotected for HI Antibodies Against All Fluarix Vaccine Strains

End point title	Number of Subjects Seroprotected for HI Antibodies Against All Fluarix Vaccine Strains
-----------------	--

End point description:

A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	35	23	10
Units: Subjects				
H1N1 Day 0	7	33	23	10
H1N1 Day 28	7	35	23	0
Victoria Day 0	2	5	7	1
Victoria Day 28	7	35	21	0
H3N2 Day 0	0	17	13	0
H3N2 Day 28	7	35	23	0

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group	Fluarix All Ages Group	Havrix Junior All Ages Group
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	43	24	65	77
Units: Subjects				
H1N1 Day 0	43	24	63	77
H1N1 Day 28	0	0	65	0
Victoria Day 0	9	7	14	17
Victoria Day 28	0	0	63	0

H3N2 Day 0	6	12	30	18
H3N2 Day 28	0	0	65	0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Seroprotected for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine

End point title	Number of Subjects Seroprotected for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine
-----------------	---

End point description:

A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 0 and Month 6

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	28	22	9
Units: Subjects				
H1N1 Day 0 (N=6;28;22;9;38;23;56;70)	6	26	22	9
H1N1 Month 6 (N=6;28;22;9;38;23;56;70)	6	28	22	8
Victoria Day 0 (N=6;28;22;0;0;0;56;0)	2	5	7	0
Victoria Month 6 (N=6;28;22;0;0;0;56;0)	6	26	20	0
H3N2 Day 0 (N=6;28;22;0;0;0;56;0)	0	13	12	0
H3N2 Month 6 (N=6;28;22;0;0;0;56;0)	6	28	22	0

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group	Fluarix All Ages Group	Havrix Junior All Ages Group
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	38	23	56	70
Units: Subjects				
H1N1 Day 0 (N=6;28;22;9;38;23;56;70)	38	23	54	70
H1N1 Month 6 (N=6;28;22;9;38;23;56;70)	36	21	56	65
Victoria Day 0 (N=6;28;22;0;0;0;56;0)	0	0	14	0

Victoria Month 6 (N=6;28;22;0;0;0;56;0)	0	0	52	0
H3N2 Day 0 (N=6;28;22;0;0;0;56;0)	0	0	25	0
H3N2 Month 6 (N=6;28;22;0;0;0;56;0)	0	0	56	0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Mean Geometric Increase (MGI) in HI Antibody Titers Against All Fluarix Vaccine Strains in All Subjects Receiving Fluarix Vaccine

End point title	Mean Geometric Increase (MGI) in HI Antibody Titers Against All Fluarix Vaccine Strains in All Subjects Receiving Fluarix Vaccine <sup>[7]</sup>
-----------------	--

End point description:

MGI was defined as the geometric mean of the within-subject ratios of the post-vaccination (Day 28) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 28

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was analysed only for the Fluarix groups i.e. Fluarix 6-11 Months Group, Fluarix 12-35 Months Group, Fluarix 3-9 Years Group and Fluarix All Ages Group.

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Fluarix All Ages Group
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	7	35	23	65
Units: Ratio				
geometric mean (confidence interval 95%)				
H1N1	10.2 (3 to 34.8)	10.8 (7.9 to 14.7)	6.5 (4.7 to 8.8)	8.9 (7.1 to 11.2)
Victoria	10.8 (5.9 to 19.6)	9.4 (6.8 to 12.9)	8.6 (5.5 to 13.6)	9.3 (7.3 to 11.7)
H3N2	17.7 (7.2 to 43.5)	21.1 (16.3 to 27.4)	16.7 (11.4 to 24.6)	19.1 (15.6 to 23.4)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Mean Geometric Increase (MGI) in HI Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine

End point title	Mean Geometric Increase (MGI) in HI Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine
-----------------	--

End point description:

MGI was defined as the geometric mean of the within-subject ratios of the post-vaccination (Month 6) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer. Vaccine strains included in the

analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.

End point type	Secondary
End point timeframe:	
Month 6	

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	28	22	9
Units: Ratio				
geometric mean (confidence interval 95%)				
H1N1 (N=6;28;22;9;38;23;56;70)	7.1 (2 to 25.5)	4.5 (3.3 to 6)	3.5 (2.6 to 4.7)	0.5 (0.4 to 0.8)
Victoria (N=6;28;22;0;0;0;56;0)	17 (3.1 to 93.9)	9.2 (5.9 to 14.2)	6.2 (3.8 to 10.2)	0 (0 to 0)
H3N2 (N=6;28;22;0;0;0;56;0)	25.4 (14 to 46)	7.9 (5.5 to 11.4)	8.5 (5.9 to 12.3)	0 (0 to 0)

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group	Fluarix All Ages Group	Havrix Junior All Ages Group
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	38	23	56	70
Units: Ratio				
geometric mean (confidence interval 95%)				
H1N1 (N=6;28;22;9;38;23;56;70)	0.9 (0.7 to 1.1)	0.7 (0.7 to 0.8)	4.3 (3.4 to 5.3)	0.8 (0.7 to 0.9)
Victoria (N=6;28;22;0;0;0;56;0)	0 (0 to 0)	0 (0 to 0)	8.4 (6.1 to 11.6)	0 (0 to 0)
H3N2 (N=6;28;22;0;0;0;56;0)	0 (0 to 0)	0 (0 to 0)	9.2 (7.2 to 11.8)	0 (0 to 0)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Serum Neutralising Antibody Titers Against All Fluarix Vaccine Strains

End point title	Serum Neutralising Antibody Titers Against All Fluarix Vaccine Strains <sup>[8]</sup>
End point description:	
Antibody titers were expressed as Geometric Mean Titers (GMTs).	
End point type	Secondary
End point timeframe:	
Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)	

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was analysed only for the Fluarix groups i.e. Fluarix 6-11 Months Group, Fluarix 12-35 Months Group, Fluarix 3-9 Years Group and Fluarix All Ages Group.

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Fluarix All Ages Group
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	7	35	23	65
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1 Day 0 (N=7;34;23;0;0;0;64;0)	359.1 (159.7 to 807.4)	235.4 (180.5 to 307)	237.6 (154.7 to 364.8)	247.3 (199.6 to 306.5)
H1N1 Day 28 (N=7;34;23;0;0;0;64;0)	5706.2 (3382.6 to 9626)	5860.4 (5072.5 to 6770.7)	2052.3 (1395.1 to 3019)	4007.7 (3274.8 to 4904.6)
Victoria Day 0 (N=7;35;23;0;0;0;65;0)	20.2 (8.3 to 49.2)	19.1 (13.9 to 26.2)	25.4 (16.6 to 38.9)	21.3 (16.8 to 26.9)
Victoria Day 28 (N=7;34;23;0;0;0;64;0)	49.3 (6.9 to 349.5)	42.3 (20.9 to 85.5)	80.8 (34.8 to 187.9)	54.3 (33 to 89.3)
H3N2 Day 0 (N=7;35;23;0;0;0;65;0)	30 (13.5 to 66.9)	84.9 (53.7 to 134.5)	139.5 (100.8 to 193)	90.5 (67.4 to 121.6)
H3N2 Day 28 (N=7;34;23;0;0;0;64;0)	90.1 (50.1 to 162)	1011.6 (509.5 to 2008.6)	1229.9 (586.5 to 2579.3)	832.9 (514.7 to 1347.8)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Serum Neutralising Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine

End point title	Serum Neutralising Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine
-----------------	---

End point description:

Antibody titers were expressed as GMTs. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 0 and Month 6

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	28	22	9
Units: Titer				
geometric mean (confidence interval 95%)				

H1N1 Day 0 (N=6;27;22;9;38;23;55;70)	419.1 (172 to 1021.2)	254.8 (184 to 352.8)	221.2 (145 to 337.6)	292 (170.8 to 499.1)
H1N1 Month 6 (N=6;28;22;9;38;23;56;70)	5080.1 (2169.7 to 11894.4)	2359.7 (1852 to 3006.4)	892.2 (585.7 to 1359)	292.6 (173.6 to 493)
Victoria Day 0 (6;28;22;0;0;0;56;0)	21.4 (7.2 to 64)	20.7 (13.9 to 30.7)	26.1 (16.8 to 40.6)	0 (0 to 0)
Victoria Month 6 (N=6;28;22;0;0;0;56;0)	284.5 (89.4 to 905.6)	140 (81.7 to 240)	113.1 (58.2 to 219.7)	0 (0 to 0)
H3N2 Day 0 (N=6;28;22;0;0;0;56;0)	34.1 (13.6 to 85.3)	78.4 (47 to 131.1)	136.5 (97.4 to 191.3)	0 (0 to 0)
H3N2 Month 6 (N=6;28;22;0;0;0;56;0)	264.1 (136 to 512.9)	618.2 (435.1 to 878.5)	638.2 (381.1 to 1068.8)	0 (0 to 0)

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group	Fluarix All Ages Group	Havrix Junior All Ages Group
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	38	23	56	70
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1 Day 0 (N=6;27;22;9;38;23;55;70)	441.3 (317.5 to 613.5)	212.8 (142.3 to 318.1)	254.2 (200.2 to 322.9)	329.3 (260 to 417.2)
H1N1 Month 6 (N=6;28;22;9;38;23;56;70)	528.9 (377.5 to 741)	221.6 (155 to 316.8)	1748.2 (1347.3 to 2268.4)	368.3 (290.1 to 467.5)
Victoria Day 0 (6;28;22;0;0;0;56;0)	0 (0 to 0)	0 (0 to 0)	22.7 (17.4 to 29.7)	0 (0 to 0)
Victoria Month 6 (N=6;28;22;0;0;0;56;0)	0 (0 to 0)	0 (0 to 0)	138.9 (95.2 to 202.6)	0 (0 to 0)
H3N2 Day 0 (N=6;28;22;0;0;0;56;0)	0 (0 to 0)	0 (0 to 0)	89.2 (65.5 to 121.5)	0 (0 to 0)
H3N2 Month 6 (N=6;28;22;0;0;0;56;0)	0 (0 to 0)	0 (0 to 0)	571.5 (435.5 to 749.8)	0 (0 to 0)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Seropositive for Serum Neutralising Antibodies Against All Fluarix Vaccine Strains

End point title	Number of Subjects Seropositive for Serum Neutralising Antibodies Against All Fluarix Vaccine Strains <sup>[9]</sup>
End point description:	Seropositivity was defined as antibody titers greater than or equal to 1:28.
End point type	Secondary
End point timeframe:	Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was analysed only for the Fluarix groups i.e. Fluarix 6-11 Months Group,

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Fluarix All Ages Group
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	7	35	23	65
Units: Subjects				
H1N1 Day 0 (N=7;34;23;0;0;0;64;0)	7	34	23	64
H1N1 Day 28 (N=7;34;23;0;0;0;64;0)	7	34	23	64
Victoria Day 0 (N=7;35;23;0;0;0;65;0)	1	5	7	13
Victoria Day 28 (N=7;34;23;0;0;0;64;0)	3	15	12	30
H3N2 Day 0 (N=7;35;23;0;0;0;65;0)	4	26	22	52
H3N2 Day28 (N=7;34;23;0;0;0;64;0)	7	34	23	64

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects Seropositive for Serum Neutralising Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine

End point title	Number of Subjects Seropositive for Serum Neutralising Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine
End point description:	
Seropositivity was defined as antibody titers greater than or equal to 1:28. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.	
End point type	Secondary
End point timeframe:	
Day 0 and Month 6	

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	28	22	9
Units: Subjects				
H1N1 Day 0 (N=6;27;22;9;38;23;55;70)	6	27	22	9
H1N1 Month 6 (N=6;28;22;9;38;23;56;70)	6	28	22	9
Victoria Day 0 (6;28;22;0;0;0;56;0)	1	5	7	0
Victoria Month 6 (N=6;28;22;0;0;0;56;0)	6	28	18	0
H3N2 Day 0 (N=6;28;22;0;0;0;56;0)	4	20	21	0
H3N2 Month 6 (N=6;28;22;0;0;0;56;0)	6	28	22	0

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group	Fluarix All Ages Group	Havrix Junior All Ages Group
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	38	23	56	70
Units: Subjects				
H1N1 Day 0 (N=6;27;22;9;38;23;55;70)	38	23	55	70
H1N1 Month 6 (N=6;28;22;9;38;23;56;70)	38	23	56	70
Victoria Day 0 (6;28;22;0;0;0;56;0)	0	0	13	0
Victoria Month 6 (N=6;28;22;0;0;0;56;0)	0	0	52	0
H3N2 Day 0 (N=6;28;22;0;0;0;56;0)	0	0	45	0
H3N2 Month 6 (N=6;28;22;0;0;0;56;0)	0	0	56	0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Seroconverted for Serum Neutralising Antibodies Against All Fluarix Vaccine Strains in Subjects Receiving Fluarix

End point title	Number of Subjects Seroconverted for Serum Neutralising Antibodies Against All Fluarix Vaccine Strains in Subjects Receiving Fluarix <sup>[10]</sup>
-----------------	--

End point description:

Seroconverted subject was a subject with a minimum 4-fold increase in titer at post-vaccination for neutralizing antibody response.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 28

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was analysed only for the Fluarix groups i.e. Fluarix 6-11 Months Group, Fluarix 12-35 Months Group, Fluarix 3-9 Years Group and Fluarix All Ages Group.

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Fluarix All Ages Group
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	7	34	23	64
Units: Subjects				
H1N1 (N=7;33;23;0;0;0;63;0)	6	33	17	56
Victoria (N=7;34;23;0;0;0;64;0)	3	11	11	25
H3N2 (N=7;34;23;0;0;0;64;0)	4	32	16	52



## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects Seroconverted for Serum Neutralising Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine

End point title	Number of Subjects Seroconverted for Serum Neutralising Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine
-----------------	---

End point description:

Seroconverted subject was a subject with a minimum 4-fold increase in titer at post-vaccination for neutralizing antibody response. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 6

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	28	22	9
Units: Subjects				
H1N1 (N=6;27;22;9;38;23;55;70)	5	22	10	0
Victoria (N=6;28;22;0;0;0;56;0)	6	23	13	0
H3N2 (N=6;28;22;0;0;0;56;0)	5	21	13	0

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group	Fluarix All Ages Group	Havrix Junior All Ages Group
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	38	23	56	70
Units: Subjects				
H1N1 (N=6;27;22;9;38;23;55;70)	2	0	37	2
Victoria (N=6;28;22;0;0;0;56;0)	0	0	42	0
H3N2 (N=6;28;22;0;0;0;56;0)	0	0	39	0

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms

End point title	Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms
-----------------	---

End point description:

Solicited local symptoms assessed included: pain, redness and swelling. Any symptom was defined as regardless of intensity. Grade 3 pain was defined as a symptom that prevented normal activity. Grade 3 redness and swelling were defined as redness/swelling above 50 millimeter (mm).

End point type Secondary

End point timeframe:

During the 7 days (Day 0 – 6) after vaccination

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	43	23	10
Units: Subjects				
Any Pain	3	28	21	5
Grade 3 Pain	0	1	1	0
Any Redness	7	33	19	2
Grade 3 Redness	2	8	6	0
Any Swelling	5	23	11	1
Grade 3 Swelling	1	3	2	0

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	43	24		
Units: Subjects				
Any Pain	19	14		
Grade 3 Pain	1	0		
Any Redness	15	9		
Grade 3 Redness	0	0		
Any Swelling	10	5		
Grade 3 Swelling	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Any Solicited Local Symptom

End point title Duration of Any Solicited Local Symptom

End point description:

Duration was expressed as median number of days the symptom persisted. Solicited local symptoms assessed included: pain, redness and swelling.

End point type Secondary

End point timeframe:

During the 7 days (Days 0 – 6) after vaccination

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	30	20	5
Units: Days				
median (inter-quartile range (Q1-Q3))				
Pain [Dose 1] (N= 3;23;20;5;19;14)	1 (1 to 2)	2 (1 to 5)	2 (1 to 5)	1 (1 to 5)
Redness [Dose 1] (N= 6;30;16;2;15;9)	4 (1 to 6)	3 (1 to 7)	3 (1 to 6)	1.5 (1 to 2)
Swelling [Dose 1] (N=5;18;9;1;10;5)	2 (1 to 5)	3 (1 to 6)	2 (1 to 6)	1 (1 to 1)
Pain [Dose 2] (N= 2;21;14;0;0;0)	1.5 (1 to 2)	1 (1 to 3)	2 (1 to 3)	0 (0 to 0)
Redness [Dose 2] (N= 4;23;13;0;0;0)	3 (3 to 7)	3 (1 to 6)	2 (1 to 5)	0 (0 to 0)
Swelling [Dose 2] (N=2;16;8;0;0;0)	3 (2 to 4)	2 (1 to 6)	2 (1 to 4)	0 (0 to 0)

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	14		
Units: Days				
median (inter-quartile range (Q1-Q3))				
Pain [Dose 1] (N= 3;23;20;5;19;14)	1 (1 to 7)	2 (1 to 4)		
Redness [Dose 1] (N= 6;30;16;2;15;9)	3 (1 to 7)	2 (1 to 5)		
Swelling [Dose 1] (N=5;18;9;1;10;5)	2 (1 to 7)	2 (1 to 3)		
Pain [Dose 2] (N= 2;21;14;0;0;0)	0 (0 to 0)	0 (0 to 0)		
Redness [Dose 2] (N= 4;23;13;0;0;0)	0 (0 to 0)	0 (0 to 0)		
Swelling [Dose 2] (N=2;16;8;0;0;0)	0 (0 to 0)	0 (0 to 0)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Less Than 6 Years Reporting Any, Grade 3 and Related Solicited General Symptoms

End point title	Number of Subjects Less Than 6 Years Reporting Any, Grade 3 and Related Solicited General Symptoms
-----------------	--

End point description:

Solicited general symptoms assessed included diarrhoea, drowsiness, irritability, loss of appetite and fever. Any was defined as any symptom regardless of intensity; any fever was axillary temperature greater than or equal to 37.5 degrees celsius. Grade 3 was a symptom preventing normal everyday activity; grade 3 loss of appetite was not eating at all; grade 3 fever was axillary temperature above 39 degrees celsius. Related was any symptom assessed by the investigator as causally related to the study vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

During the 7 days (Days 0–6) after vaccination

<b>End point values</b>	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	43	11	10
Units: Subjects				
Any Diarrhoea	5	8	2	2
Grade 3 Diarrhoea	0	0	0	0
Related Diarrhoea	5	3	1	2
Any Drowsiness	6	16	2	2
Grade 3 Drowsiness	0	3	1	0
Related Drowsiness	5	10	2	2
Any Irritability	6	20	4	5
Grade 3 Irritability	0	1	0	0
Related Irritability	5	14	3	4
Any Loss of Appetite	6	14	4	3
Grade 3 Loss of Appetite	0	1	0	0
Related Loss of Appetite	4	8	4	2
Any Fever	5	14	4	3
Grade 3 Fever	1	1	1	0
Related Fever	4	11	3	0

<b>End point values</b>	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	43	2		
Units: Subjects				
Any Diarrhoea	7	0		
Grade 3 Diarrhoea	1	0		
Related Diarrhoea	3	0		
Any Drowsiness	15	0		
Grade 3 Drowsiness	2	0		
Related Drowsiness	9	0		
Any Irritability	14	0		
Grade 3 Irritability	2	0		
Related Irritability	10	0		
Any Loss of Appetite	6	0		
Grade 3 Loss of Appetite	0	0		
Related Loss of Appetite	3	0		
Any Fever	11	0		
Grade 3 Fever	0	0		
Related Fever	4	0		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Duration of Any Solicited General Symptom Experienced by Subjects Less Than 6 Years Old

End point title	Duration of Any Solicited General Symptom Experienced by Subjects Less Than 6 Years Old
End point description:	Duration was expressed as median number of days the symptom persisted. Solicited general symptoms assessed include diarrhoea, drowsiness, irritability, loss of appetite and fever.
End point type	Secondary
End point timeframe:	During a 7-day follow-up period (Day 0-6) after vaccination

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	14	3	5
Units: Days				
median (inter-quartile range (Q1-Q3))				
Diarrhoea [Dose 1] (N=3;6;1;2;7;0)	2 (2 to 3)	2 (1 to 4)	1 (1 to 1)	3.5 (1 to 6)
Drowsiness [Dose 1] (N=4;11;1;2;15;0)	1.5 (1 to 6)	1 (1 to 4)	3 (3 to 3)	2 (2 to 2)
Irritability [Dose 1] (N=4;14;3;5;14;0)	2.5 (1 to 4)	2 (1 to 5)	1 (1 to 2)	2 (1 to 6)
Loss of Appetite [Dose 1] (N=5;11;3;3;6;0)	2 (1 to 6)	3 (1 to 5)	1 (1 to 3)	2 (1 to 7)
Fever [Dose 1] (N=3;10;2;3;11;0)	4 (1 to 6)	1.5 (1 to 3)	1.5 (1 to 2)	2 (2 to 2)
Diarrhoea [Dose 2] (N=4;4;1;0;0;0)	1 (1 to 3)	1 (1 to 4)	1 (1 to 1)	0 (0 to 0)
Drowsiness [Dose 2] (N=4;9;2;0;0;0)	1.5 (1 to 3)	1 (1 to 2)	1 (1 to 1)	0 (0 to 0)
Irritability [Dose 2] (N=5;12;2;0;0;0)	2 (2 to 7)	2 (1 to 4)	2 (1 to 3)	0 (0 to 0)
Loss of Appetite [Dose 2] (N=4;9;2;0;0;0)	2 (1 to 5)	2 (1 to 4)	1 (1 to 1)	0 (0 to 0)
Fever [Dose 2] (N=3;9;2;0;0;0)	2 (1 to 2)	1 (1 to 7)	1 (1 to 1)	0 (0 to 0)

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	15	0 <sup>[11]</sup>		
Units: Days				
median (inter-quartile range (Q1-Q3))				
Diarrhoea [Dose 1] (N=3;6;1;2;7;0)	1 (1 to 3)	( to )		
Drowsiness [Dose 1] (N=4;11;1;2;15;0)	2 (1 to 6)	( to )		
Irritability [Dose 1] (N=4;14;3;5;14;0)	1 (1 to 5)	( to )		
Loss of Appetite [Dose 1] (N=5;11;3;3;6;0)	1.5 (1 to 3)	( to )		
Fever [Dose 1] (N=3;10;2;3;11;0)	2 (1 to 6)	( to )		

Diarrhoea [Dose 2] (N=4;4;1;0;0;0)	0 (0 to 0)	( to )		
Drowsiness [Dose 2] (N=4;9;2;0;0;0)	0 (0 to 0)	( to )		
Irritability [Dose 2] (N=5;12;2;0;0;0)	0 (0 to 0)	( to )		
Loss of Appetite [Dose 2] (N=4;9;2;0;0;0)	0 (0 to 0)	( to )		
Fever [Dose 2] (N=3;9;2;0;0;0)	0 (0 to 0)	( to )		

Notes:

[11] - This group was not analysed.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Above 6 Years Reported Any, Grade 3 and Related Solicited General Symptoms

End point title	Number of Subjects Above 6 Years Reported Any, Grade 3 and Related Solicited General Symptoms
-----------------	---

End point description:

Solicited general symptoms assessed included arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering, sweating and fever. Any was defined as any symptom regardless of intensity; any fever was axillary temperature greater than or equal to 37.5 degrees celsius. Grade 3 was a symptom preventing normal everyday activity; grade 3 fever was axillary temperature above 39 degrees celsius. Related was any symptom assessed by the investigator as causally related to the study vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

During a 7-day follow-up period (Day 0-6) after vaccination

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[12]</sup>	0 <sup>[13]</sup>	12	0 <sup>[14]</sup>
Units: Subjects				
Any Arthralgia			0	
Grade 3 Arthralgia			0	
Related Arthralgia			0	
Any Fatigue			5	
Grade 3 Fatigue			0	
Related Fatigue			4	
Any Gastrointestinal Symptoms			1	
Grade 3 Gastrointestinal Symptoms			0	
Related Gastrointestinal Symptoms			1	
Any Headache			4	
Grade 3 Headache			0	
Related Headache			3	
Any Myalgia			1	
Grade 3 Myalgia			0	
Related Myalgia			1	
Any Shivering			2	
Grade 3 Shivering			0	
Related Shivering			2	

Any Sweating			0	
Grade 3 Sweating			0	
Related Sweating			0	
Any Fever			3	
Grade 3 Fever			0	
Related Fever			2	

Notes:

[12] - This group was not analysed

[13] - This group was not analysed

[14] - This group was not analysed.

<b>End point values</b>	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[15]</sup>	22		
Units: Subjects				
Any Arthralgia		0		
Grade 3 Arthralgia		0		
Related Arthralgia		0		
Any Fatigue		8		
Grade 3 Fatigue		0		
Related Fatigue		6		
Any Gastrointestinal Symptoms		1		
Grade 3 Gastrointestinal Symptoms		0		
Related Gastrointestinal Symptoms		1		
Any Headache		4		
Grade 3 Headache		0		
Related Headache		3		
Any Myalgia		2		
Grade 3 Myalgia		0		
Related Myalgia		2		
Any Shivering		0		
Grade 3 Shivering		0		
Related Shivering		0		
Any Sweating		0		
Grade 3 Sweating		0		
Related Sweating		0		
Any Fever		0		
Grade 3 Fever		0		
Related Fever		0		

Notes:

[15] - This group was not analysed

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Any Solicited General Symptom Experienced by Subjects Above 6 Years Old

End point title	Duration of Any Solicited General Symptom Experienced by Subjects Above 6 Years Old
-----------------	---

End point description:

Duration was expressed as median number of days the symptom persisted. Solicited general symptoms assessed included fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever.

End point type Secondary

End point timeframe:

During a 7-day follow-up period (Day 0-6) after vaccination

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[16]</sup>	0 <sup>[17]</sup>	4	0 <sup>[18]</sup>
Units: Days				
median (inter-quartile range (Q1-Q3))				
Fatigue [Dose 1] (N=0;0;4;0;0;8)	( to )	( to )	1.5 (1 to 5)	( to )
Fatigue [Dose 2] (N=0;0;2;0;0;0)	( to )	( to )	4 (1 to 7)	( to )
Gastrointestinal Symptoms [Dose 1] (N=0;0;1;0;0;1)	( to )	( to )	2 (2 to 2)	( to )
Gastrointestinal symptoms [Dose 2] (N=0;0;0;0;0;0)	( to )	( to )	0 (0 to 0)	( to )
Headache [Dose 1] (N=0;0;2;0;0;4)	( to )	( to )	3 (2 to 4)	( to )
Headache [Dose 2] (N=0;0;2;0;0;0)	( to )	( to )	3.5 (3 to 4)	( to )
Myalgia [Dose 1] (N=0;0;0;0;0;2)	( to )	( to )	0 (0 to 0)	( to )
Myalgia [Dose 2] (N=0;0;1;0;0;0)	( to )	( to )	1 (1 to 1)	( to )
Shivering [Dose 1] (N=0;0;2;0;0;0)	( to )	( to )	1 (1 to 1)	( to )
Shivering [Dose 2] (N=0;0;0;0;0;0)	( to )	( to )	0 (0 to 0)	( to )
Fever [Dose 1] (N=0;0;3;0;0;0)	( to )	( to )	1 (1 to 1)	( to )
Fever [Dose2] (N=0;0;1;0;0;0)	( to )	( to )	1 (1 to 1)	( to )

Notes:

[16] - This group was not analysed.

[17] - This group was not analysed.

[18] - This group was not analysed.

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[19]</sup>	8		
Units: Days				
median (inter-quartile range (Q1-Q3))				
Fatigue [Dose 1] (N=0;0;4;0;0;8)	( to )	1 (1 to 2)		
Fatigue [Dose 2] (N=0;0;2;0;0;0)	( to )	0 (0 to 0)		
Gastrointestinal Symptoms [Dose 1] (N=0;0;1;0;0;1)	( to )	1 (1 to 1)		
Gastrointestinal symptoms [Dose 2] (N=0;0;0;0;0;0)	( to )	0 (0 to 0)		
Headache [Dose 1] (N=0;0;2;0;0;4)	( to )	3 (1 to 7)		
Headache [Dose 2] (N=0;0;2;0;0;0)	( to )	0 (0 to 0)		
Myalgia [Dose 1] (N=0;0;0;0;0;2)	( to )	1 (1 to 1)		
Myalgia [Dose 2] (N=0;0;1;0;0;0)	( to )	0 (0 to 0)		
Shivering [Dose 1] (N=0;0;2;0;0;0)	( to )	0 (0 to 0)		
Shivering [Dose 2] (N=0;0;0;0;0;0)	( to )	0 (0 to 0)		



Fever [Dose 1] (N=0;0;3;0;0;0)	( to )	0 (0 to 0)		
Fever [Dose2] (N=0;0;1;0;0;0)	( to )	0 (0 to 0)		

Notes:

[19] - This group was not analysed.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

End point title	Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
-----------------	--

End point description:

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as any symptom regardless of intensity or relationship to vaccination. Grade 3 was a symptom preventing normal everyday activity. Related was any symptom assessed by the investigator as causally related to the study vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

During a 28 day follow-up period (Day 0-27) after vaccination

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	44	23	10
Units: Subjects				
Any AEs	6	20	7	3
Grade 3 AEs	3	4	1	0
Related AEs	2	1	2	0

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	43	24		
Units: Subjects				
Any AEs	15	7		
Grade 3 AEs	1	1		
Related AEs	1	0		

## Statistical analyses

**Secondary: Number of Subjects Reporting Medically-Attended Events (MAEs), Adverse Events of Specific Interest (AESIs)/ Potential Immune Mediated Diseases (pIMDs) and Adverse Events (AEs) of Special Interest**

End point title	Number of Subjects Reporting Medically-Attended Events (MAEs), Adverse Events of Specific Interest (AESIs)/ Potential Immune Mediated Diseases (pIMDs) and Adverse Events (AEs) of Special Interest
-----------------	---

End point description:

MAEs: subject received medical attention defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. AESIs/pIMD: includes both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Adverse events of special interest include both convulsion and anaphylaxis.

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (up to Month 6)

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	44	23	10
Units: Subjects				
Any AEs	4	11	2	3
Grade 3 AEs	0	0	0	0
Related AEs	0	0	0	0

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	43	24		
Units: Subjects				
Any AEs	7	1		
Grade 3 AEs	0	0		
Related AEs	0	0		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Number of Subjects Reporting Serious Adverse Events (SAEs)**

End point title	Number of Subjects Reporting Serious Adverse Events (SAEs)
-----------------	--

End point description:

SAEs: medical occurrences that result in death, are life threatening, require hospitalization or

prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

End point type	Secondary
End point timeframe:	
Up to Day 28	

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	44	23	10
Units: Subjects				
subjects	0	1	0	0

End point values	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	43	24		
Units: Subjects				
subjects	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Reporting Serious Adverse Events (SAEs)

End point title	Number of Subjects Reporting Serious Adverse Events (SAEs)
End point description:	
SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.	
End point type	Secondary
End point timeframe:	
Up to Month 6	

End point values	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group	Havrix Junior 6-11 Months Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	44	23	10
Units: Subjects				
subjects	1	1	0	0

<b>End point values</b>	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	43	24		
Units: Subjects				
subjects	0	0		

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Serious adverse events were assessed throughout the study period (from the beginning of the study up to Month 6). Systematically and non-systematically assessed frequent adverse events (AEs) were assessed during 7 days and 28 days post-vaccination.

Adverse event reporting additional description:

The following systematically assessed non-serious AEs were assessed only in subjects aged less than 6 years old: diarrhoea, drowsiness, irritability and loss of appetite. The following systematically assessed non-serious AEs were assessed only in subjects aged above 6 years old: fatigue, gastrointestinal symptoms, headache, myalgia and shivering.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	10
--------------------	----

### Reporting groups

Reporting group title	Fluarix 6-11 Months Group
-----------------------	---------------------------

Reporting group description:

Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.

Reporting group title	Fluarix 12-35 Months Group
-----------------------	----------------------------

Reporting group description:

Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.

Reporting group title	Fluarix 3-9 Years Group
-----------------------	-------------------------

Reporting group description:

Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.

Reporting group title	Havrix Junior 6-11 Months Group
-----------------------	---------------------------------

Reporting group description:

Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.

Reporting group title	Havrix Junior 12-35 Months Group
-----------------------	----------------------------------

Reporting group description:

Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.

Reporting group title	Havrix Junior 3-9 Years Group
-----------------------	-------------------------------

Reporting group description:

Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.

Reporting group title	Fluarix Group
-----------------------	---------------

Reporting group description:

Subjects received 1 or doses of Fluarix vaccine based on age and priming status

Reporting group title	Havrix Junior Group
-----------------------	---------------------

Reporting group description:

Subjects received 1 dose of Havrix Junior vaccine. The second dose was administered outside the study setting.

<b>Serious adverse events</b>	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 10 (10.00%)	1 / 44 (2.27%)	0 / 23 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Head injury			
subjects affected / exposed	1 / 10 (10.00%)	0 / 44 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 44 (2.27%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Havrix Junior 6-11 Months Group	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 10 (0.00%)	0 / 43 (0.00%)	0 / 24 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Head injury			
subjects affected / exposed	0 / 10 (0.00%)	0 / 43 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 43 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Fluarix Group	Havrix Junior Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 12 (0.00%)	0 / 22 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from			

adverse events			
Injury, poisoning and procedural complications			
Head injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Fluarix 6-11 Months Group	Fluarix 12-35 Months Group	Fluarix 3-9 Years Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 10 (70.00%)	33 / 44 (75.00%)	21 / 23 (91.30%)
Nervous system disorders			
Loss of consciousness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 44 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Pain			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[1]</sup>	3 / 10 (30.00%)	28 / 43 (65.12%)	21 / 23 (91.30%)
occurrences (all)	3	28	21
Redness			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[2]</sup>	7 / 10 (70.00%)	33 / 43 (76.74%)	19 / 23 (82.61%)
occurrences (all)	7	33	19
Swelling			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[3]</sup>	5 / 10 (50.00%)	23 / 43 (53.49%)	11 / 23 (47.83%)
occurrences (all)	5	23	11
Diarrhoea			

alternative assessment type: Systematic			
subjects affected / exposed <sup>[4]</sup>	5 / 10 (50.00%)	8 / 43 (18.60%)	2 / 11 (18.18%)
occurrences (all)	5	8	2
Drowsiness			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[5]</sup>	6 / 10 (60.00%)	16 / 43 (37.21%)	2 / 11 (18.18%)
occurrences (all)	6	16	2
Irritability			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[6]</sup>	6 / 10 (60.00%)	20 / 43 (46.51%)	4 / 11 (36.36%)
occurrences (all)	6	20	4
Loss of Appetite			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[7]</sup>	6 / 10 (60.00%)	14 / 43 (32.56%)	4 / 11 (36.36%)
occurrences (all)	6	14	4
Fever (Solicited Symptom)			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[8]</sup>	5 / 10 (50.00%)	14 / 43 (32.56%)	4 / 11 (36.36%)
occurrences (all)	5	14	4
Fatigue			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 44 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal symptoms			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 44 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Headache			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 44 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Myalgia			
alternative assessment type: Systematic			



subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0
Shivering alternative assessment type: Systematic subjects affected / exposed <sup>[9]</sup> occurrences (all)	0 / 6 (0.00%) 0	0 / 28 (0.00%) 0	0 / 22 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0
Gastrointestinal disorders Lip haemorrhage subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0
Tooth discolouration subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 44 (0.00%) 0	1 / 23 (4.35%) 1
Dysphonia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 44 (0.00%) 0	1 / 23 (4.35%) 1
Asthma subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0
Skin and subcutaneous tissue disorders Erythema subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 44 (0.00%) 0	1 / 23 (4.35%) 1

Infections and infestations Fever (AE) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	9 / 44 (20.45%) 9	0 / 23 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	4 / 44 (9.09%) 4	0 / 23 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 44 (0.00%) 0	2 / 23 (8.70%) 2
Ear infection subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0
Varicella subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0

<b>Non-serious adverse events</b>	Havrix Junior 6-11 Months Group	Havrix Junior 12-35 Months Group	Havrix Junior 3-9 Years Group
Total subjects affected by non-serious adverse events subjects affected / exposed	5 / 10 (50.00%)	19 / 43 (44.19%)	14 / 24 (58.33%)
Nervous system disorders Loss of consciousness subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 43 (0.00%) 0	0 / 24 (0.00%) 0
General disorders and administration site conditions Pain alternative assessment type: Systematic subjects affected / exposed <sup>[1]</sup> occurrences (all)	5 / 10 (50.00%) 5	19 / 43 (44.19%) 19	14 / 24 (58.33%) 14
Redness alternative assessment type: Systematic			

subjects affected / exposed <sup>[2]</sup>	2 / 10 (20.00%)	15 / 43 (34.88%)	9 / 24 (37.50%)
occurrences (all)	2	15	9
Swelling			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[3]</sup>	1 / 10 (10.00%)	10 / 43 (23.26%)	5 / 24 (20.83%)
occurrences (all)	1	10	5
Diarrhoea			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[4]</sup>	2 / 10 (20.00%)	7 / 43 (16.28%)	0 / 2 (0.00%)
occurrences (all)	2	7	0
Drowsiness			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[5]</sup>	2 / 10 (20.00%)	15 / 43 (34.88%)	0 / 2 (0.00%)
occurrences (all)	2	15	0
Irritability			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[6]</sup>	5 / 10 (50.00%)	14 / 43 (32.56%)	0 / 2 (0.00%)
occurrences (all)	5	14	0
Loss of Appetite			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[7]</sup>	3 / 10 (30.00%)	6 / 43 (13.95%)	0 / 2 (0.00%)
occurrences (all)	3	6	0
Fever (Solicited Symptom)			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[8]</sup>	3 / 10 (30.00%)	11 / 43 (25.58%)	0 / 2 (0.00%)
occurrences (all)	3	11	0
Fatigue			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 43 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal symptoms			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 43 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0

Headache alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 43 (0.00%) 0	0 / 24 (0.00%) 0
Myalgia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 43 (0.00%) 0	0 / 24 (0.00%) 0
Shivering alternative assessment type: Systematic subjects affected / exposed <sup>[9]</sup> occurrences (all)	0 / 9 (0.00%) 0	0 / 38 (0.00%) 0	0 / 23 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 43 (4.65%) 2	0 / 24 (0.00%) 0
Gastrointestinal disorders Lip haemorrhage subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 43 (0.00%) 0	0 / 24 (0.00%) 0
Tooth discolouration subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 43 (0.00%) 0	0 / 24 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 43 (0.00%) 0	0 / 24 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	2 / 43 (4.65%) 2	1 / 24 (4.17%) 1
Dysphonia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 43 (0.00%) 0	0 / 24 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 43 (0.00%) 0	1 / 24 (4.17%) 1
Asthma			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 43 (0.00%) 0	0 / 24 (0.00%) 0
Skin and subcutaneous tissue disorders Erythema subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 43 (2.33%) 1	0 / 24 (0.00%) 0
Infections and infestations Fever (AE) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 43 (0.00%) 0	0 / 24 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	6 / 43 (13.95%) 6	0 / 24 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 43 (2.33%) 1	0 / 24 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 43 (2.33%) 1	2 / 24 (8.33%) 2
Ear infection subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 43 (0.00%) 0	0 / 24 (0.00%) 0
Varicella subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 43 (0.00%) 0	0 / 24 (0.00%) 0

<b>Non-serious adverse events</b>	Fluarix Group	Havrix Junior Group	
Total subjects affected by non-serious adverse events subjects affected / exposed	5 / 12 (41.67%)	8 / 22 (36.36%)	
Nervous system disorders Loss of consciousness subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0	
General disorders and administration site conditions			

Pain			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[1]</sup>	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Redness			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[2]</sup>	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Swelling			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[3]</sup>	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Diarrhoea			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[4]</sup>	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Drowsiness			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[5]</sup>	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Irritability			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[6]</sup>	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Loss of Appetite			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[7]</sup>	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Fever (Solicited Symptom)			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[8]</sup>	3 / 12 (25.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Fatigue			
alternative assessment type: Systematic			

subjects affected / exposed	5 / 12 (41.67%)	8 / 22 (36.36%)	
occurrences (all)	5	8	
Gastrointestinal symptoms			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 12 (8.33%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Headache			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 12 (33.33%)	4 / 22 (18.18%)	
occurrences (all)	4	4	
Myalgia			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 12 (8.33%)	2 / 22 (9.09%)	
occurrences (all)	1	2	
Shivering			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[9]</sup>	2 / 12 (16.67%)	0 / 22 (0.00%)	
occurrences (all)	2	0	
Pyrexia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			
Lip haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Tooth discolouration			
subjects affected / exposed	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Vomiting			
subjects affected / exposed	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 12 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	

Dysphonia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0	
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0	
Asthma subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0	
Skin and subcutaneous tissue disorders Erythema subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0	
Infections and infestations Fever (AE) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	3 / 12 (25.00%) 3	0 / 22 (0.00%) 0	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0	
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0	
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0	
Ear infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0	
Varicella subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: For the solicited local and general symptoms, not all subjects had their symptom sheet completed therefore, the analysis of the solicited symptoms based on the Total Vaccinated cohort



included only subjects with documented safety data (i.e. symptom sheet/screen completed).

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: For the solicited local and general symptoms, not all subjects had their symptom sheet completed therefore, the analysis of the solicited symptoms based on the Total Vaccinated cohort included only subjects with documented safety data (i.e. symptom sheet/screen completed).

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: For the solicited local and general symptoms, not all subjects had their symptom sheet completed therefore, the analysis of the solicited symptoms based on the Total Vaccinated cohort included only subjects with documented safety data (i.e. symptom sheet/screen completed).

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: For the solicited local and general symptoms, not all subjects had their symptom sheet completed therefore, the analysis of the solicited symptoms based on the Total Vaccinated cohort included only subjects with documented safety data (i.e. symptom sheet/screen completed).

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: For the solicited local and general symptoms, not all subjects had their symptom sheet completed therefore, the analysis of the solicited symptoms based on the Total Vaccinated cohort included only subjects with documented safety data (i.e. symptom sheet/screen completed).

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: For the solicited local and general symptoms, not all subjects had their symptom sheet completed therefore, the analysis of the solicited symptoms based on the Total Vaccinated cohort included only subjects with documented safety data (i.e. symptom sheet/screen completed).

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: For the solicited local and general symptoms, not all subjects had their symptom sheet completed therefore, the analysis of the solicited symptoms based on the Total Vaccinated cohort included only subjects with documented safety data (i.e. symptom sheet/screen completed).

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: For the solicited local and general symptoms, not all subjects had their symptom sheet completed therefore, the analysis of the solicited symptoms based on the Total Vaccinated cohort included only subjects with documented safety data (i.e. symptom sheet/screen completed).

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: For the solicited local and general symptoms, not all subjects had their symptom sheet completed therefore, the analysis of the solicited symptoms based on the Total Vaccinated cohort included only subjects with documented safety data (i.e. symptom sheet/screen completed).

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported